Wells Fargo Slashes Price Target On This Stock By Over 71%, Also Check Out Other Major PT Changes Here
Wells Fargo cut the price target on Cabaletta Bio, Inc. (NASDAQ: CABA) from $14 to $4. Wells Fargo analyst Derek Archila maintained the stock with an Overweight rating. Cabaletta Bio shares gained 0.9% to trade at $0.92 on Wednesday.
Why Nikola Dropped Over 9%; Here Are 66 Biggest Movers From Yesterday
Gainers
Mobile Global Esports Inc. (NASDAQ: MGAM) shares surged 103.9% to settle at $5.30 on Tuesday. Shares are in low-float territory; the issue has about 15 million shares in its float.
Cabaletta Bio To Present Data At 31st EADV Congress And Provides Update On DesCAARTes Trial
abaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that it will present new
